Literature DB >> 26445474

Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways.

E Rebecca Longbottom1, Hew D T Torrance, Helen C Owen, Paraskevi C Fragkou, Charles J Hinds, Rupert M Pearse, Michael J O'Dwyer.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the role of interleukin (IL)-6 pathways in postoperative immune suppression and to assess the reversibility of this phenomenon.
BACKGROUND: The postoperative period is characterized by increased IL-6 production and features of immune suppression. In vitro, IL-6 mediates anti-inflammatory effects through inhibition of interferon gamma (IFN-γ) pathways. The significance of the immunomodulatory effects of IL-6 in the clinical setting of postoperative immune suppression remains unclear.
METHODS: Patients over 45 years old undergoing elective surgery, involving the gastrointestinal tract, were recruited. IL-6 levels were assayed using an enzyme linked immunosorbent assay preoperatively, and at 24 and 48 hours. Peripheral blood mononuclear cells from healthy volunteers were cultured in perioperative serum and CD14Human Leukocyte Antigen-DR (HLA-DR) [monocyte HLA-DR (mHLA-DR)] geometric mean florescent intensity was measured in the presence and absence of IL-6 neutralizing antibody and recombinant IFN-γ.
RESULTS: Of the 108 patients, 41 developed a postoperative infection. The IL-6 levels increased 19-fold from the preoperative sample to 24 hours postoperatively (P < 0.0001). Higher IL-6 levels at 24 (P = 0.0002) and 48 hours (P = 0.003) were associated with subsequent postoperative infectious complications. mHLA-DR mean florescent intensity fell when healthy peripheral blood mononuclear cells were cultured with postoperative serum compared with preoperative serum (P = 0.008). This decrease was prevented by the presence of IFN-γ in the culture media, but not by the presence of IL-6-neutralizing antibody.
CONCLUSIONS: IL-6 levels increase after a major surgery and are associated with an increased susceptibility to postoperative infections. Serum obtained from postoperative patients induces an immunosuppressive response, reflected in reduced mHLA-DR levels, mediated through IL-6 independent pathways and is reversible with IFN-γ. These data may have therapeutic implications for the prevention of infection in patients undergoing major surgery.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26445474     DOI: 10.1097/SLA.0000000000001484

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

Review 1.  SARS-CoV-2: Review of Conditions Associated With Severe Disease and Mortality.

Authors:  Joshua Eyitemi; Britanie Thomas; Yazmin Ramos; Xue Feng; Chiamaka Ezekwesili
Journal:  Int J Prev Med       Date:  2022-08-08

Review 2.  Cytokines as biomarkers of inflammatory response after open versus endovascular repair of abdominal aortic aneurysms: a systematic review.

Authors:  Diamantis I Tsilimigras; Fragiska Sigala; Georgios Karaolanis; Ioannis Ntanasis-Stathopoulos; Eleftherios Spartalis; Michael Spartalis; Nikolaos Patelis; Alexandros Papalampros; Chandler Long; Demetrios Moris
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

Review 3.  Current research priorities in perioperative intensive care medicine.

Authors:  Michael A Gillies; Michael Sander; Andrew Shaw; Duminda N Wijeysundera; John Myburgh; Cesar Aldecoa; Ib Jammer; Suzana M Lobo; Naomi Pritchard; Michael P W Grocott; Marcus J Schultz; Rupert M Pearse
Journal:  Intensive Care Med       Date:  2017-06-08       Impact factor: 17.440

4.  Dual Challenge of Cancer and COVID-19: Impact on Health Care and Socioeconomic Systems in Asia Pacific.

Authors:  Roselle De Guzman; Monica Malik
Journal:  JCO Glob Oncol       Date:  2020-06

5.  [COVID-19 and hematopoietic stem cell transplantation: Recommendations].

Authors:  Jihane Toughza; Aomar Agadr; Nabil Ismaili
Journal:  Bull Cancer       Date:  2020-06-20       Impact factor: 1.276

Review 6.  ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.

Authors:  Loredana Vecchione; Sebastian Stintzing; George Pentheroudakis; Jean-Yves Douillard; Florian Lordick
Journal:  ESMO Open       Date:  2020-05

7.  How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?

Authors:  Aysun Dauti Işıklar; Cem Deniz; Aykut Soyder; Nilgün Güldoğan; Ebru Yılmaz; Gül Başaran
Journal:  Eur J Breast Health       Date:  2021-06-25

8.  How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center.

Authors:  Giulia Pasello; Jessica Menis; Sara Pilotto; Stefano Frega; Lorenzo Belluomini; Federica Pezzuto; Anna Caliò; Matteo Sepulcri; Nunzia Luna Valentina Cernusco; Marco Schiavon; Maurizio Valentino Infante; Marco Damin; Claudio Micheletto; Paola Del Bianco; Riccardo Giovannetti; Laura Bonanno; Umberto Fantoni; Valentina Guarneri; Fiorella Calabrese; Federico Rea; Michele Milella; PierFranco Conte
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

9.  [Management of a colon cancer patient complicated with COVID-19].

Authors:  Ziqi Ye; Yun Hong; Xiuhua Wu; Dongsheng Hong; Yanfang Zhang; Xihao Dong; Yuefeng Rao; Xiaoyang Lu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

10.  A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients.

Authors:  Francesco A Mistretta; Stefano Luzzago; Luigi Orlando Molendini; Matteo Ferro; Enza Dossena; Fabrizio Mastrilli; Gennaro Musi; Ottavio de Cobelli
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.